Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07789106

A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists

The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are:

Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment?

Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications.

Participants will:

Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test Attend a short monthly video call (about 20-30 minutes) with a study dietitian Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app Log all exercise sessions in the smartphone app throughout the study

This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Obesity & Overweight Body Weight Fatigue Severity Scale GLP - 1 Muscle Contraction Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Ubiquinol

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 30-65 years
  • Body mass index >27kg/m2 and <35 kg/m2
  • Currently initiating, or has initiated within the preceding 4 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management.
  • Is physically mobile and able to complete 5x sit to stand movements
  • Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app
  • Proficient in English language speaking and reading
  • Owns their own digital body weighing scale
  • Able and willing to provide full informed consent

Exclusion criteria

  • Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening
  • Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy)
  • Prior or current use of statin medication
  • Has previously used GLP-1 agonists and/or undergone bariatric surgery
  • Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10
  • Failed screening bloods (any results that is outside of the lab reference range)
  • Intention to stop GLP-1 agonist use within 9 months of randomisation
  • Pregnancy, breastfeeding or intention to conceive during study

Treatment and study plan

Ubiquinol 100 MG Oral Capsule

Dietary Supplement

The active intervention is a commercially available ubiquinol dietary supplement, manufactured and supplied by Kaneka (Japan). The dose is one 100mg capsule per day taken.

Placebo

Dietary Supplement

The placebo is manufactured by the same manufacturer that produces the active product (Kaneka, Japan). The placebo is visually similar to the active product and will be packaged in the same bottles as the active intervention to maintain the blind. The dose is one 100mg capsule per day taken with the first meal of the day. The product is stored at room temperature.

Primary outcomes

  1. Self-reported fatigue

    Time frame: 9 months

    Measured via Chalder Fatigue Scale score

Secondary outcomes

  1. Quality of life questionnaire

    Time frame: 9 months

    Measured via WHOQoL-BREF

  2. Skeletal muscle function

    Time frame: 9 months

    Measured via 5 x sit-to-stand test

  3. Body Mass

    Time frame: 9 months

    Body Mass measured in kg

  4. Blood pyruvate levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  5. Blood Lactate levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  6. Blood Coenzyme Q10 levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  7. Blood Creatine Kinase levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  8. Blood Vitamin D levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  9. Blood Ferritin levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  10. Blood Magnesium levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  11. Blood Total Cholesterol levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  12. Blood LDL levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  13. Blood HDL levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  14. Blood Triglycerides levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  15. Blood Vitamin B12 levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  16. Blood HBA1C levels

    Time frame: 9 months

    At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by Complement Genomics (Durham, UK) following their own standard operating procedures.

  17. Height

    Time frame: 9 months

    Measured in metres

  18. Body Mass Index

    Time frame: 9 months

    Measured in kg/m²

Study contacts

Contact information is provided by the study sponsor or research team.

Tom Jameson, PhD

CONTACT

[email protected]

7794865520 ext. +44

Sponsors and collaborators

Lead sponsor

StudySetGo

Network

Registry information

Official study title

A Randomised, Placebo-Controlled Trial to Evaluate the Effect of Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Who Are Self-Administering GLP-1 Agonists ("Project Zest")

Acronym: Project Zest

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Aug 27, 2026
Registry last updated
Aug 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.